Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide

被引：5

作者：

Bonjoch, Anna ^{[1
]}

Negredo, Eugenia

Puig, Jordi

Erkizia, Itziar

Puig, Teresa

Cabrera, Cecilia

Ruiz, Lidia

Clotet, Bonaventura

机构：

[1] Autonomous Univ Barcelona, Lluita SIDA Fdn, AIDS Care Unit, Hosp Univ Germans Trias & Pujol, Badalona, Spain

[2] Hosp Univ Germans Trias & Pujol, Irsi Caixa Fdn, Badalona, Spain

来源：

AIDS | 2006年 / 20卷 / 14期

关键词：

D O I：

10.1097/01.aids.0000244212.15951.2b

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The aim of this pilot study was to assess whether enfuvirtide can be discontinued in patients on long-term viral suppression. Eight patients with multidrug-resistant virus were randomly assigned to stop and 10 subjects to continue enfuvirtide. At week 48, viral rebound occurred in five (62.5%) and in no patients, respectively, (P = 0.007). The CD4 cell decrease in failure patients was 5% (P = ns). These results suggest that enfuvirtide should be maintained until new active drugs became available.

引用

页码：1896 / 1898

页数：3

共 6 条

[1] Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations [J].

Clotet, B ;

Raffi, F ;

Cooper, D ;

Delfraissy, JF ;

Lazzarin, A ;

Moyle, G ;

Rockstroh, J ;

Soriano, V ;

Schapiro, J .

AIDS, 2004, 18 (08) :1137-1146

[2] Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection [J].

Deeks, SG ;

Hoh, R ;

Neilands, TB ;

Liegler, T ;

Aweeka, F ;

Petropoulos, CJ ;

Grant, RM ;

Martin, JN .

JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (09) :1537-1544

[3]

HATANO H, 2006, 13 C RETR OPP INF DE

[4] Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America [J].

Lalezari, JP ;

Henry, K ;

O'Hearn, M ;

Montaner, JSG ;

Piliero, PJ ;

Trottier, B ;

Walmsley, S ;

Cohen, C ;

Kuritzkes, DR ;

Eron, JJ ;

Chung, J ;

DeMasi, R ;

Donatacci, L ;

Drobnes, C ;

Delehanty, J ;

Salgo, M ;

Farthing, C ;

Graham, E ;

Packard, M ;

Ngo, L ;

Lederman, M ;

Buam, J ;

Pollard, R ;

Rauf, S ;

Silkowski, W ;

Thompson, M ;

Rucker, A ;

Harris, M ;

Larsen, G ;

Preseon, S ;

Cunningham, D ;

Guimaraes, D ;

Bertasso, A ;

Kinchelow, T ;

Myers, R ;

Phoenix, BCBP ;

Skolnik, PR ;

Adams, B ;

Leite, OHM ;

Oliveira, M ;

Lefebvre, E ;

Gomez, B ;

Foy, KB ;

Lampiris, H ;

Charles, S ;

Dobkin, J ;

Crawford, M ;

Slom, T ;

Murphy, R ;

Mikaitis, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (22) :2175-2185

[5] Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia [J].

Lazzarin, A ;

Clotet, B ;

Cooper, D ;

Reynes, J ;

Arasteh, K ;

Nelson, M ;

Katlama, C ;

Stellbrink, H ;

Delfraissy, J ;

Lange, J ;

Huson, L ;

DeMasi, R ;

Wat, C ;

Delehanty, J ;

Drobnes, C ;

Salgo, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (22) :2186-2195

[6] Elevated CD38 antigen expression on CD8(+) T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the multicenter AIDS cohort study than CD4(+) cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression [J].

Liu, ZY ;

Cumberland, WG ;

Hultin, LE ;

Prince, HE ;

Detels, R ;

Giorgi, JV .

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1997, 16 (02) :83-92

← 1 →